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A follicular spike in cyclic AMp (cAMp) and its subsequent degradation to AMp promotes oocyte 
maturation and ovulation. In vitro matured (iVM) oocytes do not receive the cAMp increase 
that occurs in vivo, and artificial elevation of cAMP in IVM cumulus-oocyte complexes improves 
oocyte developmental potential. This study examined whether mouse oocytes can use the cAMP 
degradation product AMP to generate ATP via the adenosine salvage pathway, and examined 
whether pharmacological elevation of cAMP in IVM cumulus-oocyte complexes alters ATP levels. 
oocytes cultured with isotopic 13c5-AMP dose-dependently produced 13c5-ATP, however total cellular 
Atp remained constant. pharmacological elevation of cAMp using forskolin and iBMX prior to iVM 
decreased oocyte Atp and Atp:ADp ratio, and promoted activity of the energy regulator AMpK. 
Conversely, cumulus cells exhibited higher ATP and no change in AMPK. Culture of oocytes without 
their cumulus cells or inhibition of their gap-junctional communication yielded lower oocyte 13c5-
Atp, indicating that cumulus cells facilitate Atp production via the adenosine salvage pathway. in 
conclusion, this study demonstrates that mouse oocytes can generate Atp from AMp via the adenosine 
salvage pathway, and cAMp elevation alters adenine nucleotide metabolism and may provide AMp for 
energy production via the adenosine salvage pathway during the energetically demanding process of 
meiotic maturation.
Within the ovarian antral follicle, the oocyte is surrounded by cumulus cells that are connected to the oocyte 
and each other by gap junctions, forming an entity called the cumulus-oocyte complex (COC)1. Cyclic aden-
osine monophosphate (cAMP) is a key regulator of mammalian oocyte maturation. It plays paradoxical roles 
within the oocyte and cumulus cells to orchestrate oocyte meiotic arrest and resumption2. The oocyte synthesises 
cAMP through constitutive activation of a G-protein coupled receptor, which acts to maintain meiotic arrest by 
supressing activity of the maturation-promoting factor2, and in addition cumulus cells likely supply the oocyte 
with cAMP3. Cyclic AMP is acutely and transiently upregulated in mural granulosa cells and in the oocyte in 
response to the ovulatory luteinising hormone (LH) surge4,5, initiating signalling events that promote oocyte 
meiotic resumption. These include (i) upregulation of the EGF-like peptide signalling cascade in granulosa and 
cumulus cells6, and (ii) downregulation of follicular cGMP levels7,8. Unlike the transient spike in COC cAMP that 
naturally occurs in response to the preovulatory LH surge, COCs matured in vitro exhibit a precipitous decline 
in cAMP9, thus the intricate molecular signals which are normally upregulated in cumulus cells in response to 
cAMP (e.g. EGF-like peptides) to orchestrate oocyte maturation are deficient.
In many species, oocytes can be matured in vitro via the reproductive technology in vitro maturation (IVM), 
whereby immature germinal vesicle stage COCs are collected with little to no hormonal stimulation and cultured 
until the oocyte reaches metaphase II10,11. IVM is clinically attractive but has a lower efficiency at generating preg-
nancies relative to conventional IVF12. The artificial upregulation of cAMP in IVM COCs has shown potential to 
improving pregnancy rates, although further refinement on such approaches are warranted13. One of the more 
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established approaches to cAMP modulation of IVM COCs involves the incorporation of a pre-maturation phase, 
usually termed “pre-IVM”, prior to IVM whereby COCs are treated during pre-IVM with exogenous cAMP or 
cAMP modulating agents that cause a large spike in cellular cAMP14,15. We developed a cAMP-modulated IVM 
system that incorporates a short pre-IVM phase, wherein COCs are treated with the pharmacological cAMP 
modulators 3-isobutyl-1-methylxanthine (IBMX) and forskolin9,16. Forskolin (FSK) is a potent stimulator of 
cAMP synthesis that acts by activating adenylate cyclase, an enzyme that catalyses the conversion of ATP to 
cAMP17. IBMX is a broad spectrum inhibitor of cyclic nucleotide phosphodiesterases, the enzymes that hydro-
lyse cAMP to AMP18 (Fig. 1). This FSK/IBMX pre-IVM phase has been shown to increase COC cAMP levels 
substantially, thus mimicking to some extent the in vivo spike in cAMP caused by the gonadotrophin surge9,19. 
Several studies have shown FSK/IBMX pre-IVM can significantly improve oocyte quality as it leads to enhanced 
subsequent blastocyst development, blastocyst quality and pregnancy rates, relative to standard IVM (i.e. lacking 
pre-IVM)9,16,20–22, suggesting that this may be one approach to bridge the efficiency gap between IVM and IVF 
and therefore having clinical and commercial relevance.
The metabolic consequences of cAMP modulation in the COC remain poorly understood. As illustrated 
(Fig. 1), FSK/IBMX treatment promotes the consumption and generation of adenine nucleotides. ATP is used as 
a substrate for cAMP synthesis by forskolin, hence FSK/IBMX pre-IVM would be expected to lead to depletion 
of oocyte ATP. Degradation of cAMP is required for meiotic resumption to occur2, and its degradation product 
is 5′-AMP. A recent study has demonstrated that bovine oocytes may have the capacity to utilise AMP for ATP 
production via the adenosine salvage pathway23, a two-step enzymatic process in which AMP can be phosphoryl-
ated to ADP by adenylate kinase, and ADP is phosphorylated to ATP by creatine kinase (Fig. 1). Hence, natural 
or pharmacological elevation of COC cAMP may enable the oocyte to utilise AMP for energy production, par-
ticularly at a time of ATP reduction. AMP, ADP and ATP are also modulators of AMP-activated protein kinase 
(AMPK) which is an energy sensing enzyme that directs metabolic changes in response to cellular energy status 
by controlling the activity of key rate-limiting enzymes involved in lipid and carbohydrate metabolism24. AMPK 
activity is allosterically regulated by the adenine nucleotides AMP, ADP, and ATP which compete for binding 
on AMPK’s gamma subunit. Binding of ATP to the gamma subunit elicits structural changes allowing phos-
phatases to access Thr-172, while binding of AMP or ADP elicit conformational changes allowing greater affinity 
to AMPK’s upstream kinase LKB1, and therefore greater activity induced by post-translational modification25. 
Hence, alterations in cellular [ATP:ADP] or [ATP:AMP] ratios significantly influence AMPK activity. Despite the 
prominent role of AMPK in regulating cellular energy metabolism, investigation of the impact of COC cAMP 
modulation on AMPK activity is lacking.
This study aimed to investigate whether the adenosine salvage pathway is active in the mouse oocyte, and 
whether upregulation of cAMP in the COC impacts ATP production.
Results
the oocyte produces Atp from AMp via the adenosine salvage pathway. The ability of the oocyte 
to use AMP for ATP generation via the adenosine salvage pathway was examined by culturing COCs or DOs with 
1 mM isotopic-labelled AMP (13C5-AMP), and measuring its conversion to 13C5-ADP and 13C5-ATP. In oocytes 
cultured either with their cumulus cells intact (oocytes from COCs) or as denuded oocytes, uptake of 13C5-AMP 
and its conversion to 13C5-ADP and 13C5-ATP was observed (Fig. 2A,B). Intact COCs were notably more efficient 
Figure 1. Cellular adenosine metabolism in relation to cAMP-elevating pre-IVM treatment. COC cAMP 
increases during the peri-ovular period and through pharmacological elevation during pre-IVM. Cyclic AMP 
is generated by adenylate cyclase (AC) from its substrate ATP and is hydrolysed to AMP by phosphodiesterases 
(PDE). AMP can be recycled to ATP via the adenosine salvage pathway. The energy sensing enzyme AMP-
activated protein kinase (AMPK) is activated by shifts in ATP:AMP and ATP:ADP ratios. CK, creatine kinase; 
AK, adenylate kinase; Cr, creatine; PCr, phosphocreatine; IBMX, 3-isobutyl-1-methylxanthine; IVM, oocyte in 
vitro maturation.
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at generating ATP in the oocyte than oocytes denuded of cumulus cells. Treatment of COCs with 13C5-AMP 
resulted in ~8-fold more intra-oocyte 13C5-ATP than treatment of DOs (Fig. 2A,B). In addition, in the case of 
COCs, the proportion of intra-oocyte 13C5-ATP relative to the total amount of isotopic-labelled nucleotides was 
67%. By contrast in denuded oocytes, 13C5-ATP makes up only 48% of the total isotopic nucleotides. Blockage of 
cumulus-oocyte gap-junctional communication using CBX led to a 3.8-fold reduction in generation of ATP from 
AMP, however this was not statistically significant (p = 0.087) (Fig. 2C).
Iodoacetamide (IAC) was used to inhibit the adenosine salvage pathway by inhibiting creatine kinase activity 
and thus the inter-conversion of ADP and ATP. Exposure to IAC did not affect 13C5-AMP uptake by COCs or 
DOs, or its conversion to 13C5-ADP, however its conversion to 13C5-ATP was ablated in both oocytes from COCs 
and in DOs (Fig. 2A,B). Accumulation of ADP was not seen in the presence of IAC, perhaps suggesting that 
nucleotide homeostasis may have been maintained by an equilibrium shift favouring the conversion of AMP to 
either adenosine or inosine monophosphate in the purine nucleotide biosynthetic pathway26. To assess the effect 
of increasing the availability of AMP on oocyte ATP levels (Fig. 2D,E), COCs were cultured with increasing doses 
of 13C5-AMP. A dose-dependent increase in intra-oocyte 13C5-ATP peak area, with a corresponding decrease 
in endogenous ATP peak area was observed, such that the net amount of ATP detected was constant (Fig. 2D). 
Cumulative intra-oocyte ATP was quantified following culture ± the top dose of 1 mM 13C5-AMP. The same trend 
was seen whereby the uptake and conversion of 13C5-AMP to 13C5-ATP led to a decrease in endogenous ATP 
which resulted in a cumulative ATP level (13C5-AMP + endogenous ATP) similar to endogenous ATP in oocytes 
not given 13C5-AMP (Fig. 2E).
Elevated COC cAMP depletes intra-oocyte ATP and alters AMPK protein. As treatment of COCs 
with FSK/IBMX (pre-IVM) leads to a large acute increase in cAMP9,19, it would be expected that adenine nucleo-
tide substrates and metabolites would be affected in the oocyte. Oocyte adenine nucleotide and AMPK levels were 
measured ± pre-IVM to examine the impact of FSK/IBMX cAMP elevation. Oocytes from COCs (i.e. exposed 
to a FSK/IBMX treatment as intact COCs in the pre-IVM phase only followed by IVM, and then denuded of 
cumulus cells) exhibited significantly lower intra-oocyte ATP throughout oocyte maturation compared to con-
trols (P < 0.05 main effect, two-way ANOVA; Fig. 3A). Oocyte ADP was significantly higher following FSK/
IBMX pre-IVM than controls (P < 0.05 main effect, two-way ANOVA; Fig. 3B), and consequently the ATP:ADP 
ratio was significantly lower (P < 0.01 main effect, two-way ANOVA; Fig. 3C). Intra-oocyte ATP levels and the 
Figure 2. Oocytes utilise AMP for ATP production via the adenosine salvage pathway. Iodoacetamide (IAC) 
was used to inhibit creatine kinase activity in order to perturb the interconversion of ADP and ATP. COCs 
(A) or denuded oocytes (B) were cultured for 3 h ± 13C5-AMP and then intra-oocyte 13C5-AMP, 13C5-ADP and 
13C5-ATP were measured by LC-MS/MS (n = 4 biological replicates). COCs were cultured with 13C5-AMP ± the 
gap-junction uncoupler carbenoxolone (CBX) for 3 h and intra-oocyte 13C5-ATP was measured (n = 4 biological 
replicates) (C). COCs were cultured for 3 h with increasing concentrations of 13C5-AMP and the peak areas 
of intra-oocyte 13C5-ATP and endogenous ATP were measured (n = 1 biological replicate) (D). COCs were 
cultured for 3 h ± 13C5-AMP (1 mM) and intra-oocyte 13C5-ATP was measured (n = 4 biological replicates) (E). 
ns, not significantly different (P ˃  0.05, t-test), #Not detected; data are mean ± SEM.
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ATP:ADP ratio changed with duration of IVM (P < 0.005 main effects; Fig. 3A,C), associated with a drop in ATP 
at 2 hours of culture and a steady increase in the ATP:ADP ratio with time, regardless of treatment. Intra-oocyte 
AMP was below the limit of quantification, however, given that the ATP:ADP ratio is commonly used as a sur-
rogate for ATP:AMP, one would anticipate that intra-oocyte AMP is also elevated in response to elevated COC 
Figure 3. Elevated COC cAMP alters intra-oocyte adenine nucleotide levels throughout oocyte maturation. 
COCs were either not exposed (control, 0 h pre-IVM) or were exposed to 2 h of pre-IVM with FSK + IBMX 
prior to IVM culture in the presence of FSH for up to 16 h. Cumulus cells were then removed and intra-oocyte 
ATP (A), ADP (B), and the ATP:ADP ratio (C) were measured (mean ± SEM). T, treatment; D, oocyte culture 
duration; *Significantly different (P < 0.05, two-way ANOVA); ns, not significantly different. Oocyte meiotic 
maturation was assessed after 2, 3, 4 and 16 hours of culture (D). *Significantly different to control (P < 0.05, 
χ2). N = 3 biological replicates.
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cAMP. Oocytes remain meiotically arrested at the GV stage after pre-IVM with FSK/IBMX16, but then FSK/
IBMX pre-IVM accelerated oocyte meiotic progression, with increased oocyte GVBD rates at 2 h of IVM rela-
tive to control (P < 0.01; Fig. 3D); GVBD rates were comparable by 3 h and MII rates at 16 h of culture. Oocytes 
exposed to FSK/IBMX pre-IVM exhibited significantly higher (P < 0.05) total AMPK at 16 h (Fig. 4D), but not at 
2 h (Fig. 4C) of oocyte maturation. The ratio of phosphorylated AMPK (pAMPK) to total AMPK (tAMPK) was 
unaltered at both time points (Fig. 4A,B).
elevated coc cAMp increases coc Atp. COC adenine nucleotide and AMPK levels were meas-
ured ± pre-IVM to examine the impact of FSK/IBMX cAMP elevation. In contrast to within the oocyte, ATP 
levels in the whole COC were significantly higher following FSK/IBMX pre-IVM treatment (P < 0.05 main effect, 
two-way ANOVA; Fig. 5A). There were no significant differences in ADP and AMP levels, or in the ATP:ADP 
and ATP:AMP ratios between control and FSK/IBMX pre-IVM treated COCs (Fig. 5B–E). There was also no 
Figure 4. Elevated COC cAMP alters intra-oocyte AMPK production. COCs were either untreated (control) 
or pre-treated for 2 h (pre-IVM) with FSK + IBMX, then cultured without treatments in the presence of 
FSH for 2 h or 16 h. Cumulus cells were then removed and intra-oocyte phosphorylated (pAMPK) and total 
(tAMPK) AMPK were measured at 2 h (A,C) or 16 h (B,D). N = 3 biological replicates, data are mean ± SEM. 
*Significantly different (P < 0.05, t-test).
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significant difference in cellular energy charge between control and FSK/IBMX pre-IVM exposed COCs (Fig. 5F). 
Energy charge is an index of cellular energy status that is calculated by the relative levels of ATP, ADP and AMP27. 
Intra-oocyte energy charge was not obtainable since AMP was not quantifiable in denuded oocytes (Fig. 2). 
Irrespective of pre-IVM treatment, ATP and AMP levels changed over the first 3 hours of IVM, with COC ATP 
levels increasing and AMP levels decreasing, leading to time-dependent changes in the ATP:ADP and ATP:AMP 
ratios (all: P < 0.001 main effects; Fig. 5). Consistent with the lack of effect of FSK/IBMX pre-IVM on whole COC 
AMP, ADP, ATP/AMP or ATP/ADP, there was no significant difference in total or phosphorylated AMPK levels 
in control versus FSK/IBMX exposed COCs at 2 h or 16 h of oocyte maturation (Fig. 6). In summary, COC ATP 
was increased by FSK/IBMX pre-IVM, however no effect on AMPK was observed.
Discussion
Oocyte meiotic maturation is an energetically demanding process with large quantities of ATP required for met-
aphase I spindle formation and migration to the oocyte cortex28. Unlike cumulus cells, the oocyte has a very poor 
capacity for glycolysis and instead relies on cumulus cells to perform glycolysis and supply pyruvate as a substrate 
for oxidative phosphorylation by oocyte mitochondria for most metabolic energy (Fig. 7)29. Fully grown and 
maturing mammalian oocytes exhibit atypically immature mitochondria which are hooded, contain fewer cristae, 
and consequently have a reduced capacity for energy production via oxidative phosphorylation30–32. Ovulation 
and pre-IVM treatment with FSK/IBMX lead to marked increases in COC and intra-oocyte cAMP, with pre-IVM 
yielding ~4-fold higher COC cAMP than ovulatory LH4,5,9. Given that metabolism of intra-oocyte cAMP to 
AMP is required for meiotic resumption to occur (reviewed by Downs2), we postulated that there is potential for 
the oocyte to capitalise on the availability of large amounts of AMP following cAMP breakdown during oocyte 
meiotic maturation to generate ATP via the adenosine salvage pathway.
The adenosine salvage pathway, a two-step enzymatic process that phosphorylates AMP to ADP, and then 
ADP to ATP (Fig. 1), was recently proposed as an alternate pathway for ATP production in the maturing oocyte 
in order to meet its energy demands. Scantland, et al.23 recently provided evidence that bovine oocytes utilise 
this pathway for energy production, although some of the evidence provided was indirect as adenosine metab-
olite tracing was not performed23. In the current study we provided 13C5-AMP as a substrate for mouse COCs 
and denuded oocytes to directly trace its metabolism via the adenosine salvage pathway. Denuded oocytes and 
oocytes collected from intact COCs, cultured in the presence of 13C5-AMP, were found to contain 13C5-ATP and 
13C5-ADP generated from this isotopic-labelled substrate. Furthermore, inhibition of creatine kinase (required 
for the ADP to ATP conversion step in the adenosine salvage pathway) completely ablated 13C5-ATP production 
without significantly affecting 13C5-ADP or 13C5-AMP levels. Hence these findings provide direct evidence to 
support the original hypothesis by Scantland, et al.23 that the adenosine salvage pathway is active in oocytes. 
However, while 13C5-ATP was generated from extracellular 13C5-AMP, the total amount of ATP in the cell did 
not change. This may be because the oocyte has fine control of ATP homeostasis, or utilisation of the exogenous 
AMP may be limited by the availability of other substrates in the adenosine salvage pathway. In support of the 
latter hypothesis, exogenous culture of denuded bovine oocytes with phosphocreatine, the phosphate donor in 
Figure 5. Elevated COC cAMP alters adenine nucleotide levels. COCs were either untreated (control) or 
pre-treated for 2 h (pre-IVM) with FSK + IBMX, then cultured without treatments in the presence of FSH for 
3 h. COC ATP (A), ADP (B), AMP (C) were measured. COC ATP:ADP (D), ATP:AMP (E) ratios and energy 
charge (F) were calculated. N = 4 biological replicates, data are mean ± SEM. T, treatment; D, oocyte culture 
duration; *Significantly different (P < 0.05, two-way ANOVA); ns, not significantly different.
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the adenosine salvage pathway, led to a significant increase in ATP levels23. Hence, taken together, it appears the 
adenosine salvage pathway is active in oocytes and it may be an additional means for the oocyte to generate ATP 
for energy demand, particularly during the energetically demanding process of meiotic maturation where a large 
amount of AMP is generated by phosphodiesterase breakdown of cAMP.
Cumulus cells play a major role in ATP production via the adenosine salvage pathway. The amount of 
13C5-ATP was substantially higher in oocytes from COCs than in oocytes cultured without their cumulus vest-
ment, and pharmacological uncoupling of gap junctions in the COC led to a 3.8-fold reduction in 13C5-ATP levels 
within the oocyte. These two observations suggest that cumulus cells likely directly supply the oocyte with ATP 
they generated via the adenosine salvage pathway (Fig. 7). In line with our observations, others have demon-
strated that oocytes matured with intact cumulus cells have higher ATP than denuded oocytes23,33.
This study demonstrates that raising cAMP levels in COCs using forskolin and IBMX in a pre-IVM phase to 
maintain meiotic arrest induces energy deficit (decreased ATP and increased ADP/ATP ratio) within the oocyte. 
The lower intra-oocyte ATP concentrations immediately following cessation of FSK/IBMX treatment (0 h IVM) 
and the marked decrease during the early stages of meiotic resumption (0–2 h) can likely be attributed to the 
supraphysiological increased activity of adenylate cyclase by forskolin, which generates cAMP by using ATP 
Figure 6. Elevated COC cAMP does not impact COC AMPK production and activity. COCs were either 
untreated (control) or pre-treated for 2 h (pre-IVM) with FSK + IBMX, then cultured without treatments in 
the presence of FSH for 2 h or 16 h. COC phosphorylated (pAMPK) and total (tAMPK) AMPK levels were 
measured at 2 h (A,C) or 16 h (B,D). N = 3 biological replicates, data are mean ± SEM. Data within graphs were 
not significantly different (P ˃0.05, t-test).
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as a substrate (Fig. 1). However, an additional factor contributing to ATP depletion may be a reduction in the 
amount of AMP available due to residual IBMX activity (blocking breakdown of cAMP to AMP), which would 
perturb ATP production from AMP via the adenosine salvage pathway. A sharp recovery in intra-oocyte ATP 
was noted between 2–4 h after pre-IVM which may be associated with IBMX clearance. Overall, using combined 
forskolin and IBMX may be a harsh approach to artificially inhibit oocyte meiotic resumption during pre-IVM. 
Furthermore, the success of FSK/IBMX pre-IVM in improving embryo development has proved variable in dif-
fering research settings34. Alternative approaches which do not activate adenylate cyclase are known to be effective 
in maintaining oocyte meiotic arrest in pre-IVM and lead to increased subsequent oocyte developmental com-
petence. Culture with the synthetic cAMP analogue dibutyryl cAMP is effective in preventing germinal vesicle 
breakdown leading to enhanced oocyte quality14. More recently, a pre-IVM approach shown to be effective in pre-
venting GVBD utilises the cGMP modulator c-type natriuretic peptide (CNP) as the meiosis arresting agent35–37. 
CNP is the natural follicular factor which maintains meiotic arrest in the antral follicle38. CNP-mediated pre-IVM 
has been shown to improve oocyte developmental competence in several species including human35–37,39,40, and 
likely represents the future of IVM since it more closely mimics the mechanisms of in vivo meiotic arrest and 
hence presents a more physiological approach than FSK/IBMX.
AMPK is a master energy sensing enzyme that directs metabolic changes in response to cellular energy sta-
tus24. AMPK is activated by changes in the cellular ATP:AMP or ATP:ADP ratios and acts to restore energy 
balance by downregulating energy consuming anabolic pathways and upregulating energy producing catabolic 
pathways24. The increased energy demand (depletion in oocyte ATP, and consequent shift in ATP:ADP ratio) 
placed on the oocyte by generation of high levels of cAMP increased intra-oocyte AMPK synthesis, presuma-
bly by increasing mRNA translation during oocyte maturation, however the relative activity (phosphylation) 
of AMPK to total protein remained constant. The increase in total AMPK may be a means to restrain the ATP 
depletion caused by FSK exposure. In contrast to the oocyte, cAMP elevation in COC did not alter AMPK level, 
likely because ATP was elevated rather than depleted in the COC.
In contrast to intra-oocyte ATP, which decreased in response to pre-IVM, ATP levels in the whole COC were 
increased in response to elevated COC cAMP, demonstrating that cumulus cells respond differently to FSK/
IBMX. Recent evidence suggests that elevating COC cAMP stimulates glucose uptake and metabolism in murine 
and bovine cumulus cells. FSK/IBMX pre-IVM leads to increased mouse COC lactate production throughout 
IVM, indicative of increased glycolysis16,21. In addition, microarray analysis of bovine cumulus cells following 
6 h culture with FSK, IBMX and dipyridamole demonstrated a significantly altered gene expression profile rel-
ative to control, including the upregulation of genes involved in glucose uptake and metabolism (GFPT2, HK2, 
SLC2A1)41. Unlike cumulus cells, oocytes lack the glucose transporter SLC2A4 and hence have a poor capacity 
Figure 7. Hypothesised model of the impact of cAMP modulation in the cumulus-oocyte complex on oocyte 
energy production. Oocyte meiotic resumption and pharmacological cAMP upregulation via pre-IVM generate 
AMP from cAMP in cumulus cells which can be used via the adenosine salvage pathway to regenerate ATP 
in the oocyte. Upregulation of cAMP in the cumulus-oocyte complex leads to a decrease in intra-oocyte ATP, 
decreasing the ATP:ADP ratio and upregulating AMPK protein expression to restrain energy depletion. Pre-
IVM also increases COC ATP by stimulating cumulus cell glycolysis. TCA, tricarboxylic acid cycle; OXPHOS, 
oxidative phosphorylation; AMPK, AMP-activated protein kinase.
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for glucose uptake and glycolysis29, and thus cannot capitalise on any stimulatory effects of high cAMP on these 
processes. Hence, elevated COC cAMP appears to induce metabolic alterations in cumulus cells which enhance 
energy production (despite consuming ATP as a substrate for cAMP synthesis), a phenomenon that has previ-
ously been associated with improved oocyte developmental outcomes42–45.
In conclusion, this study demonstrates that modulation of adenine nucleotides impacts mouse oocyte ATP 
production. Oocytes have the capacity to generate ATP from AMP via the adenosine salvage pathway, and cumu-
lus cells enhance ATP production via this pathway. Furthermore, elevation of the AMP precursor cAMP impacts 
adenine nucleotide levels within the oocyte and cumulus cells, with these compartments responding differently. 
These findings contribute to our understanding of oocyte ATP metabolism and further elucidate the extent to 
which elevated cAMP, which occurs during ovulation and in using modern approaches to oocyte maturation in 
vitro, alters the metabolic properties of the COC. These new insights are important as they provide a new perspec-
tive in energy generation in the oocyte, which in turn is critical to oocyte developmental competence29,46, and are 
also significant for the development of new reproductive technologies such as oocyte IVM.
Materials and Methods
Cumulus-oocyte complex collection. Mice were maintained in accordance with the Australian Code of 
Practice for Care and Use of Animals for Scientific Purposes and all experimental protocols were approved by the 
University of New South Wales Animal Care & Ethics Committee. 129/Sv mice were used for pre-IVM exper-
iments and C57/Bl6 mice were used for metabolite tracing experiments. Peri-pubertal 28–30-day old females 
were given an intraperitoneal injection of 5 IU of equine chorionic gonadotropin (Folligon, Intervet, Boxmeer, 
The Netherlands). Ovaries were collected in HEPES-buffered alpha minimum essential medium (αMEM; Gibco, 
Life Technologies, New York, USA) supplemented with 3 mg/mL BSA 46 h post-eCG. COCs were released from 
preovulatory follicles using a 27-gauge needle into HEPES-buffered αMEM (Gibco) with 3 mg/mL of BSA and 
100 µM of IBMX (Sigma-Aldrich, Merck, Darmstadt, Germany), and collected using flame-pulled borosilicate 
Pasteur pipettes.
COC culture and pre-IVM treatments. In experiments examining the consequences of elevated COC 
cAMP, COCs either underwent standard IVM (control, no pre-IVM) or were pre-treated for 2 h with forskolin 
and IBMX (pre-IVM) prior to IVM. Control (no pre-IVM) COCs were freshly collected from follicles, washed 
three times and immediately placed into IVM culture drops (bicarbonate-buffered αMEM containing 3 mg/mL 
BSA and 50 mIU/mL FSH (Puregon, Organon, The Netherlands)). Control (no pre-IVM) COCs were not exposed 
to any pre-IVM duration, and were therefore placed into IVM culture 2 h before the pre-IVM group. For the 
pre-IVM group, COCs were collected from follicles, then cultured in the presence of 50 µM FSK (Sigma-Aldrich) 
and 50 µM IBMX (Sigma-Aldrich) for 2 h at 37 °C in 5% CO2 in air before washing and transfer into IVM media 
(bicarbonate-buffered αMEM containing 3 mg/mL BSA and 50 mIU/mL FSH) for IVM culture. Pre-IVM treat-
ment is an established research and clinical protocol used to generate mature oocytes in vitro for IVF and embryo 
transfer9,20–22,47. The doses of FSK and IBMX used were based on previous studies9,21. Following ± pre-IVM, 
all COCs underwent IVM by culturing at a volume of ~10 µL/COC in bicarbonate-buffered αMEM (Gibco) 
supplemented with 3 mg/mL BSA and 50 mIU/mL FSH (Puregon, Organon, The Netherlands). Following 
IVM ± pre-IVM, groups of intact COCs were either analysed whole or the oocytes were denuded of cumulus 
cells (oocyte from COC) and analysed.
culture of cocs and denuded oocytes with 13c5-AMP. In experiments examining conversion of AMP 
to ATP, COCs or denuded oocytes were cultured for 3 h in bicarbonate-buffered αMEM (Gibco) supplemented 
with 3 mg/mL BSA, 50 mIU/mL FSH ± ¹³C5-adenosine 5′-monophosphate (13C5-AMP; cat# A281782; Toronto 
Research Chemicals, Canada) ± 2 mM iodoacetamide (IAC; Sigma) or 200 µM carbenoxolone (CBX; Sigma). A 
concentration of 1 mM ¹³C5-AMP was used for all experiments except the dose response experiment where doses 
are indicated. The concentrations of 13C5-AMP and IAC were based on previous studies23,48. Following culture, 
denuded oocytes, or oocytes from COCs were collected and adenine nucleotides were extracted as described 
below.
Adenine nucleotide extraction and quantification by LC-MS/MS. ATP, ADP, and AMP were 
extracted from cells, processed and quantified by liquid chromatography with tandem mass spectrometry detec-
tion (LC-MS/MS), as we recently described49. Briefly, following culture, whole COCs or oocytes were placed 
into ice-cold 80% methanol, and sonicated on ice for 1 min. Samples were then incubated at −20 °C for 20 min 
and centrifuged at 14,000 g for 10 min at 4 °C. Supernatants were collected, stored at −80 °C, and evaporated to 
dryness using a Savant SpeedVac vacuum centrifuge. Samples were spiked with 20 µL of 400 nM isotope-labelled 
internal standards (13C5-AMP, 15N5-ADP and 13C1015N5-ATP) prior to drying. Samples were then reconstituted 
in 1 mL of 100 mM ammonium acetate and loaded on to a solid phase extraction column (Hypersep Hypercarb 
50 mg/1 mL, Thermo Scientific) preconditioned with 1 mL of 60% v/v acetonitrile in formic acid buffer (0.3% v/v 
formic acid adjusted to pH 9 with ammonia), then with 1 mL of ultrapure water. The cartridge membrane was 
washed with 1 mL water, then with 300 µl of 60% acetonitrile. Analytes were eluted in 500 µL of 60% acetonitrile 
in formic acid buffer (0.3% formic acid at pH 9) and evaporated to dryness. Dried samples were reconstituted in 
50–100 µl of 100 mM ammonium acetate. Analytes were separated and quantified by LC-HESI-MS/MS as previ-
ously described49.
The uptake of 13C5-AMP and its conversion to ¹³C5 adenosine 5′-diphosphate (13C5-ADP) and ¹³C5 aden-
osine 5′-triphosphate (13C5-ATP), as well as endogenous ATP, were determined by targeting the adenine moi-
ety (m/z 136.2) generated in positive ion mode heated electrospray ionisation (HESI) product scan. 13C10, 15N5 
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5′-guanosine monophosphate (Sigma-Aldrich) was used as an internal standard for the quantitation of endoge-
nous and ¹³C5 labelled nucleotides. Table 1 shows monitored transitions and collision energy used.
Measurement of total and phosphorylated αAMpK. Following 2 h or 16 h of COC IVM ± pre-IVM, 
whole COCs or oocytes were lysed in a protein lysis buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton 
X-100) containing complete protease inhibitor (Roche) and 10 μl/mL of phosphatase inhibitor (Sigma-Aldrich) 
cocktails. Samples were mixed with loading buffer containing 100 mM dithiothreitol, freeze-thawed 4 times on 
dry ice and boiled at 95 °C for 5 min. Proteins were separated by electrophoresis using an SDS PAGE Bolt gel 
(Thermo Fisher Scientific, Waltham, MA), then transferred onto polyvinylidene fluoride membranes (Merck 
Millipore, Darmstadt, Germany) and blocked for 1 h using tris-buffered saline buffer with 0.05% Tween-20 
(TBST) and 3 mg/mL of BSA. They were then incubated over night at 4 °C with anti-phospho-AMPKα (Thr172) 
rabbit mAb that detects α1 and α2 isoforms (cat# 2535 S; Cell Signalling Technology, Danvers, USA) at 1:1000 
dilution in blocking solution. After washing in TBST, membranes were incubated at room temperature for 
4 hours in goat anti-rabbit HRP-conjugated secondary antibody (Santa Cruz Biotechnology, Dallas, USA) diluted 
to 1:3000. The bands were detected using Amersham ECL Prime (GE healthcare, UK) and imaged using the 
ImageQuantTM Las4000 (GE Healthcare, UK). Membranes were then incubated with a stripping buffer (200 mM 
glycine, 3.5 mM SDS, 1% Tween20, pH 2.2), blocked and incubated overnight with rabbit anti-AMPKα1 (cat# 
07-350; Merck Millipore) at 1:1000 dilution followed by incubation using goat anti-rabbit HRP-conjugated sec-
ondary antibody (Santa Cruz Biotechnology). The membrane was then stripped, blocked, and incubated over-
night with mouse anti-actin antibody (cat# MAB1501R; Merck Millipore) at 1:1000 dilution and incubated with 
a donkey anti-mouse HRP-conjugated secondary antibody (Santa Cruz Biotechnology) at a 1:10,000 dilution. 
Relative band intensity was measured using ImageJ software (National Institute of Health, USA). Total AMPK 
band intensities were normalised to actin band intensities, whilst phosphor-AMPK band intensities were nor-
malised to total AMPK band intensities. Results are represented as the mean ± SEM of 3 replicate experiments.
Assessment of meiotic stage. At specified time points, oocytes were denuded of cumulus cells by 
mechanical shearing using a P200 pipette. Nuclear maturation was scored using an inverted microscope as ger-
minal vesicle stage (GV), germinal vesicle breakdown (GVBD; when the GV is not visible), MII (where the first 
polar body is observed in the perivitelline space), or degenerated.
Statistical analyses and calculations. Statistical analyses were conducted using GraphPad Prism 7 soft-
ware. For experiments where two treatments were compared, differences were analysed by a t-test. Where two 
independent variables were tested, a two-way ANOVA was used. All data are presented as the mean ± SEM. For 
meiotic stage assessment, statistical significance was assessed using χ2 testing. Probabilities of P < 0.05 were con-








Summary statement. Oocyte meiotic resumption generates AMP from cAMP which the oocyte can use to 
regenerate ATP via the adenosine salvage pathway. Cumulus cells enhance this process.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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